Related Experiment Video
Updated: Oct 13, 2025

Unraveling Key Players of Humoral Immunity: Advanced and Optimized Lymphocyte Isolation Protocol from Murine Peyer's Patches
Published on: November 21, 2018
Abstract:
An antibody drug directed at the collagen receptor DDR1 helps to mitigate immune exclusion in a mouse model of triple-negative breast cancer, allowing T cells to flood in and slow tumor progression. A startup company called Parthenon Therapeutics has launched to advance the therapy into clinical development.
Insights
An antibody drug targeting the discoidin domain receptor 1 (DDR1) helps overcome immune exclusion in triple-negative breast cancer. This approach allows T cells to infiltrate tumors, slowing cancer progression in preclinical models.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapies.
- Immune exclusion, where immune cells are blocked from tumors, is a major challenge in TNBC treatment.
- Discoidin domain receptor 1 (DDR1) is implicated in tumor progression and immune evasion.
Discussion:
- An antibody targeting DDR1 was investigated for its potential to reverse immune exclusion in TNBC.
- The antibody treatment demonstrated an ability to facilitate T cell infiltration into the tumor microenvironment.
- This immune cell influx correlated with a reduction in tumor growth in a preclinical mouse model.
Key Insights:
- Targeting DDR1 with an antibody can overcome immune exclusion in triple-negative breast cancer.
- Enhanced T cell infiltration into tumors leads to slowed tumor progression.
- This strategy represents a novel therapeutic approach for aggressive breast cancer subtypes.
Outlook:
- Parthenon Therapeutics is advancing this DDR1-targeting antibody into clinical development.
- Further clinical trials are necessary to validate the efficacy and safety in human patients.
- This research opens new avenues for immunotherapy in difficult-to-treat cancers.
Related Concept Videos
Collagens are the Major Structural Proteins of ECM
Connective tissue proper includes loose...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Selectins
Structural Protein Function
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...

